Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016

  • ID: 3984520
  • Drug Pipelines
  • 75 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • GW Pharmaceuticals Plc
  • INSYS Therapeutics Inc
  • OPKO Health Inc
  • PTC Therapeutics Inc
  • Sage Therapeutics Inc
  • Xenon Pharmaceuticals Inc
  • MORE
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Dravet Syndrome - Pipeline Review, H2 2016, provides an overview of the Dravet Syndrome (Central Nervous System) pipeline landscape.

Dravet syndrome, also known as severe myoclonic epilepsy of infancy (SMEI), is a rare and catastrophic form of intractable epilepsy that begins in infancy. Symptoms include ataxia (unsteadiness), sleep disturbance, and behavior problem.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Dravet Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dravet Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dravet Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 2, 2 and 1 respectively.Dravet Syndrome.

Dravet Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dravet Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Dravet Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dravet Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dravet Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dravet Syndrome (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dravet Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dravet Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • GW Pharmaceuticals Plc
  • INSYS Therapeutics Inc
  • OPKO Health Inc
  • PTC Therapeutics Inc
  • Sage Therapeutics Inc
  • Xenon Pharmaceuticals Inc
  • MORE
List of Tables

List of Figures

Introduction

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Overview

Therapeutics Development

Pipeline Products for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Overview

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics under Development by Companies

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Products under Development by Companies

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Companies Involved in Therapeutics Development

Biscayne Pharmaceuticals Inc

GW Pharmaceuticals Plc

INSYS Therapeutics Inc

OPKO Health Inc

PTC Therapeutics Inc

Sage Therapeutics Inc

Xenon Pharmaceuticals Inc

Zogenix Inc

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Antisense Oligonucleotide for Dravet Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ataluren - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIS-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUR-1916 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fenfluramine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAGE-217 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Dormant Projects

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Product Development Milestones

Featured News & Press Releases

Nov 22, 2016: New Data on Zogenixs ZX008 for Lennox Gastaut Syndrome & Dravet Syndrome to be Presented at 70th Annual American Epilepsy Society Meeting

Oct 24, 2016: Newly Published Data Show Biscayne Pharmaceuticals' Novel Antiepileptic Drug Can Eliminate Seizures In Models Of Dravet Syndrome

Jun 28, 2016: Biscayne Pharmaceuticals Presents Data On Novel Antiepileptic Agent BIS-001 AT EILAT Conference On New Antiepileptic Drugs

Jun 27, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

Jun 08, 2016: Xenon Pharmaceuticals Presents Update on Nav1.6 Sodium Channel Inhibitor at the Jefferies 2016 Healthcare Conference

Jun 07, 2016: Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome

May 05, 2016: Zogenix Announces ZX008 New Efficacy and Safety Data for Treatment of Seizures in Dravet Syndrome

Apr 21, 2016: New Data on Zogenix ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress

Mar 14, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex (cannabidiol)

Feb 25, 2016: Edison Issues ADR Update on GW Pharmaceuticals

Jan 19, 2016: Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome

Jan 11, 2016: Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome

Dec 14, 2015: Zogenix Announces FDA Acceptance of Investigational New Drug Application for ZX008 Phase 3 Clinical Trial in Dravet Syndrome

Dec 07, 2015: Biscayne Pharmaceuticals Presents Data At 2015 AES Meeting Confirming BIS-001 Is A Novel Mechanism, Highly Potent And Well-Tolerated Anti-Epileptic Drug

Dec 07, 2015: GW Pharmaceuticals Announces New Physician Reports of Epidiolex Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Biscayne Pharmaceuticals Inc, H2 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by GW Pharmaceuticals Plc, H2 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by INSYS Therapeutics Inc, H2 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by OPKO Health Inc, H2 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by PTC Therapeutics Inc, H2 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Sage Therapeutics Inc, H2 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Xenon Pharmaceuticals Inc, H2 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Zogenix Inc, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Dormant Projects, H2 2016

List of Figures

Number of Products under Development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Biscayne Pharmaceuticals Inc
  • GW Pharmaceuticals Plc
  • INSYS Therapeutics Inc
  • OPKO Health Inc
  • PTC Therapeutics Inc
  • Sage Therapeutics Inc
  • Xenon Pharmaceuticals Inc
  • Zogenix Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll